Norgine Joins Campaign to "Make Sense" of Head and Neck Cancer

July 10, 2017

Specialist pharma company Norgine (Amsterdam, The Netherlands) has announced it is partnering with the European Head and Neck Society's 

Specialist pharma company Norgine (Amsterdam, The Netherlands) has announced it is partnering with the European Head and Neck Society's Make Sense campaign.

Campaign activities are focussed on educating healthcare professionals (HCPs) and members of the general public on disease prevention, including signs and symptoms, which aims to drive earlier presentation, diagnosis and referral. The campaign aims to raise awareness of sentinel lymph node biopsy, mapping and identification in head and neck cancer treatment, and highlight the importance of nuclear medicine as a critical part of the multi-disciplinary team.

Professor C. René Leemans, President of the European Head and Neck Society, commented: “Head and neck cancer is the seventh most common type of cancer in Europe, and its incidence is increasing. Through this partnership we hope to continue to address head and neck cancer unmet needs by improving healthcare professional understanding of the evolving treatment landscape, consequently improving patient outcomes.”

makesensecampaign.eu/